𝔖 Bobbio Scriptorium
✦   LIBER   ✦

617 Atrasentan delays disease progression in men presenting with metastatic hormone refractory prostate cancer

✍ Scribed by C. Schulman; D. Dearnaley; B. Zonnenberg; L. Coetzee; S. Hulting; J. Isaacson; A. Allen; D. Sleep

Book ID
118645823
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
212 KB
Volume
3
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase 3 randomized controlled trial of
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 142 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro